Guggenheim Raises Eli Lilly's Price Target to $942.00, Maintains 'Buy' Rating

Guggenheim analyst Seamus Fernandez has maintained a "Buy" rating for Eli Lilly (LLY) and raised the price target from $936 to $942, a 0.64% increase. The analyst sees potential for further valuation gains, and the average target price from 26 analysts is $967.78 with an upside of 22.40% from the current price. The estimated GF Value for Eli Lilly and Co is $1218.37, suggesting a 54.1% upside from the current price.

Eli Lilly (LLY) has drawn significant attention from analysts following Guggenheim's recent update on the pharmaceutical giant. Guggenheim analyst Seamus Fernandez has maintained a "Buy" rating for Eli Lilly and raised the price target from $936 to $942, a 0.64% increase. This move reflects the analyst's optimism regarding the company's performance and potential for further valuation gains.

The updated price target aligns with the broader analyst consensus. According to data from 26 analysts, the average target price for Eli Lilly is $967.78, implying an upside of 22.40% from the current price of $790.65. Furthermore, the estimated GF Value for Eli Lilly and Co is $1218.37, suggesting a potential 54.1% upside from the current price [2].

The analysts' bullish sentiment is driven by several key factors. Eli Lilly has shown remarkable strength with a 36% revenue growth in the last twelve months and is currently valued at over $709 billion. The company's obesity treatment portfolio, particularly Mounjaro and Zepbound, has demonstrated strong momentum, with sales projections indicating significant growth in the second quarter [1].

Additionally, Eli Lilly's acquisition of Verve Therapeutics for up to $1.3 billion has been strategically significant, highlighting the company's commitment to advancing its pharmaceutical portfolio. The acquisition is expected to bolster Eli Lilly's market presence and drive future growth [1].

Looking ahead, investors are focused on tirzepatide prescription and net price trends, along with pivotal clinical trial readouts expected through the remainder of 2025. These factors, combined with durable patent coverage, continue to bolster investor confidence in Eli Lilly's long-term prospects.

References:
[1] https://ca.investing.com/news/analyst-ratings/guggenheim-raises-eli-lilly-stock-price-target-ahead-of-q2-results-93CH-4098615
[2] https://ca.finance.yahoo.com/news/eli-lilly-surges-ahead-jpmorgan-172613143.html